Anouk de Jong

1.3k total citations
7 papers, 116 citations indexed

About

Anouk de Jong is a scholar working on Genetics, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Anouk de Jong has authored 7 papers receiving a total of 116 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 3 papers in Pathology and Forensic Medicine and 2 papers in Molecular Biology. Recurrent topics in Anouk de Jong's work include Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (3 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Anouk de Jong is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (3 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Anouk de Jong collaborates with scholars based in United States, Netherlands and Canada. Anouk de Jong's co-authors include Tjeerd Barf, Allard Kaptein, Gerjan de Bruin, Bas van de Kar, Diana Mittag, Dennis Demont, Michael Gulrajani, Todd Covey, Bart van Lith and J. Greg Slatter and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Anouk de Jong

7 papers receiving 112 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anouk de Jong United States	5	99	66	39	29	26	7	116
Kelly A. Smucker United States	2	129 1.3×	83 1.3×	38 1.0×	60 2.1×	67 2.6×	2	159
Sean D. Reiff United States	7	135 1.4×	102 1.5×	58 1.5×	45 1.6×	32 1.2×	13	163
Yiling Yu China	6	122 1.2×	117 1.8×	47 1.2×	18 0.6×	44 1.7×	8	152
Iryna Kriachok Ukraine	4	86 0.9×	70 1.1×	31 0.8×	17 0.6×	31 1.2×	10	93
Éric Durot France	6	65 0.7×	74 1.1×	16 0.4×	11 0.4×	22 0.8×	26	92
Elżbieta Iskierka‐Jazdzewska Poland	7	71 0.7×	84 1.3×	21 0.5×	9 0.3×	26 1.0×	25	110
Tommi Salmi United States	5	86 0.9×	75 1.1×	24 0.6×	8 0.3×	23 0.9×	11	96
Yufu Lin China	3	50 0.5×	35 0.5×	18 0.5×	16 0.6×	28 1.1×	10	81
John M. Pagel United States	6	77 0.8×	70 1.1×	20 0.5×	16 0.6×	17 0.7×	20	96
Lesley Ann Sutton Sweden	5	57 0.6×	43 0.7×	31 0.8×	33 1.1×	34 1.3×	8	113

Countries citing papers authored by Anouk de Jong

Since Specialization

Citations

This map shows the geographic impact of Anouk de Jong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anouk de Jong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anouk de Jong more than expected).

Fields of papers citing papers by Anouk de Jong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anouk de Jong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anouk de Jong. The network helps show where Anouk de Jong may publish in the future.

Co-authorship network of co-authors of Anouk de Jong

This figure shows the co-authorship network connecting the top 25 collaborators of Anouk de Jong. A scholar is included among the top collaborators of Anouk de Jong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anouk de Jong. Anouk de Jong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Jong, Anouk de, Vanja de Weerd, Corine M. Beaufort, et al.. (2023). mFAST-SeqS based aneuploidy score in circulating cell-free DNA and role as early response marker in patients with metastatic prostate cancer treated with androgen receptor signaling inhibitor.. Journal of Clinical Oncology. 41(16_suppl). 5058–5058. 1 indexed citations

Podoll, Terry, Paul G. Pearson, Allard Kaptein, et al.. (2022). Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors. Journal of Pharmacology and Experimental Therapeutics. 384(1). 173–186. 15 indexed citations

Sharma, Shringi, Xavier Pépin, Haran Burri, et al.. (2022). Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors. Clinical Pharmacology in Drug Development. 11(11). 1294–1307. 14 indexed citations

Sharma, Shringi, Xavier Pépin, Haran Burri, et al.. (2021). New Acalabrutinib Formulation Enables Co-Administration with Proton Pump Inhibitors and Dosing in Patients Unable to Swallow Capsules (ELEVATE-PLUS). Blood. 138(Supplement 1). 4365–4365. 8 indexed citations

Kaptein, Allard, Terry Podoll, Gerjan de Bruin, et al.. (2019). Abstract 2194: Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity. Cancer Research. 79(13_Supplement). 2194–2194. 6 indexed citations

Kaptein, Allard, Gerjan de Bruin, Bas van de Kar, et al.. (2019). Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies. Clinical Lymphoma Myeloma & Leukemia. 19. S316–S317. 1 indexed citations

Kaptein, Allard, Gerjan de Bruin, Bas van de Kar, et al.. (2018). Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies. Blood. 132(Supplement 1). 1871–1871. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact